Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by hossain499on Apr 04, 2017 2:05pm
110 Views
Post# 26074506

GLP Toxicology Results of TLD-1433 on Rat & Dog Models

GLP Toxicology Results of TLD-1433 on Rat & Dog Models


[News Release September 10, 2015) - Please see the extremely low Toxicity of TLD-1433

Conclusions of the GLP toxicology analysis demonstrate success in both the rat and dog models evaluated. The rat model successfully determined toxicity levels after an intravenous (“IV”) injection, while the dog model successfully determined toxicity levels after an intravesical bladder installation followed by Photo Dynamic Therapy (“PDT”) laser light activation.

 

In the rat toxicology study, the No Observed Adverse Events Level (“NOAEL”) IV limit was determined to be 1.2 mg/mL (6 mg/kg).

 

In the dog toxicology study, NOAEL was determined to be 6 mg/ml (30 mg/kg) for dog bladder infusion. Within 24 hours after instillation, the maximum level of TLD-1433 detected in blood was 0.03 ug/mL. This value is 200,000 times less than the instilled dose, indicating an ultra-low level of seepage into the blood stream supporting an extremely high safety margin. 7 days after infusion, the maximum level of TLD-1433 detected in blood was 0.002 ug/mL. This value is 3 million times less than the instilled dose, indicating a barely detectable level of TLD-1433 in the blood stream. This supports the conclusion that an infusion of 6 mg/ml of TLD-1433 (high human dose) into the bladder will be almost completely removed from the blood stream within 7 days. Thus the patient may be light sensitive for up to 7 days, which is significantly less than 30 to 90 days for Photofrin®.
 

In summary, the maximum detected dose in the blood stream within 24 hours after Beagle bladder infusion is 40,000 times lower than the IV NOAEL and 600,000 lower in 7 days, making bladder infusion an extremely safe route of administration for patients presenting with NMIBC.


Bullboard Posts